Understand · Longevity Coach article
HRT: Why a 20-Year-Old Headline Shouldn't Make Today's Decision
HRT can help with troublesome menopause symptoms, but benefits and risks vary by treatment and person. Here is what current UK guidance says—and what it does not promise.
By Longevity Coach Editorial Team ·
Topics: menopause · HRT · UK health guidance · shared decision-making · healthy ageing
For many people, the word HRT still arrives with a headline attached. The Women’s Health Initiative results, publicised in the early 2000s, changed the way hormone therapy was discussed. They also left an impression that can be hard to separate from the questions someone has now: will this help my symptoms, what are the risks for me, and how should I weigh them?
The answer is not that the old concerns were imaginary, or that HRT is automatically safe. It is also not that every person should avoid it. The evidence and UK guidance are more specific than either slogan: HRT is a treatment option for menopause symptoms, and an individual decision depends on the person, formulation, route and reason for taking it.
What HRT is used for
NICE recommends discussing HRT for menopause-associated symptoms, including hot flushes and night sweats. Oestrogen can be given as tablets, patches, gel or spray. If someone has a womb, systemic oestrogen is usually combined with a progestogen to protect the lining of the womb. After a hysterectomy, the regimen may be different. Local vaginal oestrogen is another option for some vaginal or urinary symptoms.
HRT can also have benefits for bone health in some circumstances, but it is not prescribed as a general anti-ageing treatment. It is not a dementia-prevention medicine, a way to extend life, or a substitute for evaluating new symptoms. The aim is to treat the person’s symptoms and make a plan whose likely benefits and risks make sense for them.
Why the old headline is not a personal forecast
The Women’s Health Initiative studied particular hormone regimens in a particular population, many of whom were older and further from menopause than people now commonly considering treatment for symptoms. Its findings remain part of the evidence base, but they were not a universal test of every preparation, dose, route or person. Later analyses and guidance have helped clarify how age, time since menopause, health history and the treatment itself affect the discussion.
That nuance should not be used to dismiss risks. It is a reason to ask which evidence applies to a decision being made today. A trial average does not tell one individual what will happen, and a reassuring result for one route or outcome does not settle every risk for every formulation.
Risks depend on the details
NICE advises discussing benefits and risks including breast cancer, blood clots and stroke. Breast-cancer risk differs between combined HRT and oestrogen-only HRT, and the effect of combined treatment increases with duration. Oestrogen-only treatment is generally used after hysterectomy; that does not mean it is automatically appropriate for everyone who has had one.
Route matters for some risks. Oral oestrogen can affect clotting and stroke risk differently from oestrogen delivered through the skin, such as a patch, gel or spray. Transdermal treatment may be considered when clot risk is higher, but the route does not erase every other risk, including the breast-cancer considerations associated with combined HRT. The safest choice cannot be made from a single number or a blanket “natural” label.
Tell the clinician about a personal history of breast cancer or another hormone-sensitive cancer, unexplained vaginal bleeding, previous blood clots, cardiovascular disease, liver disease, migraines and regular medicines. These details do not all mean the same thing, and they are not a do-it-yourself checklist for deciding whether HRT is forbidden. They can change which options are suitable, whether specialist advice is needed and what monitoring or investigation comes first.
HRT is also not contraception. If pregnancy is possible, ask what contraception is needed alongside symptom treatment. If you have bleeding after menopause or bleeding that is unusual for you, arrange a clinical review rather than assuming it is simply a side effect.
Timing is relevant, not a magic cut-off
Age and time since menopause can affect the balance of benefit and risk. They do not create a simple rule that treatment is safe below one birthday and unsafe above it. A clinician can consider symptom severity, medical history, the treatment being considered and what matters to the person. Some people will choose HRT; others will prefer non-hormonal options or no treatment.
It is reasonable to review a treatment plan over time. A review is a chance to ask whether symptoms have changed, whether the current dose and route are still a good fit, what side effects have appeared, and whether another option would suit better. The decision is not a lifetime pledge in either direction.
Different symptoms can call for different options
Not every menopause symptom needs the same treatment. Someone mainly affected by hot flushes and night sweats may be discussing systemic HRT. Someone whose main concern is vaginal or urinary discomfort may be offered local vaginal oestrogen or another approach. The dose, route and evidence are not interchangeable, so it helps to say which symptoms are most disruptive rather than asking for “hormones” as a single package.
People can also have symptoms that deserve a separate assessment. New chest pain, persistent low mood, unusual bleeding, or marked changes in memory should not automatically be attributed to menopause. A clinician can consider menopause alongside other possible causes and help decide whether testing, another treatment or a referral is needed.
Non-hormonal options may suit some people, whether because of preference, medical history, access or side effects. If the first option is not acceptable or does not help enough, that is information for the next conversation, not a reason to quietly endure symptoms. Ask what a realistic review point looks like and how to get advice sooner if something changes.
What we know about HRT and dementia
A systematic review and meta-analysis published in 2025 examined evidence on menopause hormone therapy and mild cognitive impairment or dementia. Across studies involving more than a million participants, it found no clear evidence that treatment either increased or reduced dementia risk, including in analyses by timing, duration and type of therapy. This is not proof that every possible effect has been ruled out. It does mean HRT should not be started or avoided as a dementia-prevention strategy on the basis of current evidence.
The practical conversation remains about symptoms, personal health history and treatment preferences. Brain health has many influences, and no hormone regimen is a shortcut around that complexity.
Take useful questions to an appointment
- Which symptoms am I trying to treat, and what changes should I realistically expect?
- What forms and routes are available, and why would one suit my circumstances?
- Do I need a progestogen, and what does my womb or hysterectomy history mean for the plan?
- How do my personal and family health history, medicines or bleeding symptoms affect the options?
- What are the likely benefits and risks for this treatment, and what alternatives could I consider?
- When should I review the plan, and which symptoms should prompt an earlier contact?
Write down what matters most before the appointment: sleep, hot flushes, mood, sexual comfort, work, or something else. That can keep the discussion focused on your life rather than on proving you are “pro-HRT” or “anti-HRT”. NICE’s guidance and the NHS menopause pages are useful starting points, but neither replaces a personal consultation.
For related reading, see our guide to bone health and fracture risk, our article on movement and physical freedom, this discussion of personalised breast-cancer care, and our guide to life design and ageing. These topics connect to health decisions, but they do not determine whether HRT is right for an individual.
Today’s decision belongs to today’s evidence
The goal is not to be for or against HRT as an identity. It is to understand what a treatment may help with, what its risks are, and how those risks relate to your own circumstances. A careful discussion should leave room for uncertainty and for different choices.
A headline from 20 years ago should not make the decision for you. Neither should a promise that HRT is harmless. Ask for current, individualised advice and choose with the facts that matter to your life now.